Healthcare / BiotechnologyNasdaqGS
$1.21
-0.05 (-3.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-128.7M · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$75M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-82.4%
↓Gross Margin
N/A
•Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.86x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-149.3M · FCF $-128.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | — | $1.6M | $9.7M | $7.6M | $41.8M | $57.1M |
| Net Income | $-149.3M | $-149.3M | $-210.3M | $-161.3M | $-123.3M | $-97.3M | $-41.5M | $-631000.00 |
| EBITDA | $-145.1M | $-145.1M | $-205.2M | $-158.2M | $-120.7M | — | — | — |
| EPS | -2.43 | -2.43 | -3.47 | -2.75 | -2.94 | -2.71 | -1.95 | -4.22 |
| Operating Margin | — | — | — | -11654.7% | -1313.4% | -1288.1% | -99.6% | -2.2% |
| Net Margin | — | — | — | -10211.1% | -1273.3% | -1284.5% | -99.3% | -1.1% |
| Balance Sheet | ||||||||
| Debt/Equity | 0.16 | 0.16 | 0.20 | 0.02 | 0.05 | 0.00 | — | — |
| Current Ratio | 16.89 | 16.89 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-128.7M | $-128.7M | $-159.4M | $-117.3M | $-96.4M | $-77.4M | $-38.8M | $-3.7M |
| Returns | ||||||||
| ROE | -82.4% | -82.4% | -69.2% | -34.1% | -39.4% | -48.9% | -14.7% | 0.8% |
| Valuation | ||||||||
| P/B | 0.41 | 0.41 | 2.69 | 2.21 | 2.57 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | — | — | — | -83.7% | — | -81.9% | -26.7% | — |
| EPS Growth | 30.0% | 30.0% | -26.2% | 6.5% | — | -39.0% | 53.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.47 → -2.43
Residual
-10.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.